Effects of candesartan cilexetil on carotid remodeling in hypertensive diabetic patients: the MITEC study

Figures & data

Figure 1 Flow of patients through the trial.

Table 1 Characteristics of the study population at baseline (intent to treat population)

	Candesartan N = 100	Amlodipine N = 109	p
Male sex, n (%)	60 (60.0)	73 (67.0)	0.295
Age, years	59.7 ± 8.6	59.7 ± 8.4	0.755
BMIa, kg/m^2	31.0 ± 5.6	30.3 ± 4.8	0.540
Glucose, g/L	1.6 ± 0.5	1.5 ± 0.4	0.774
HbA1c, %	7.1 ± 1.5	7.0 ± 1.1	0.778
Creatinine, mg/L	8.8 ± 1.6	9.1 ± 2.3	0.564
Creatinine clearancea, mL/min	108 ± 37	107 ± 34	0.902
Serum lipids, g/L
Total cholesterol	2.0 ± 0.3	2.1 ± 0.4	0.763
LDL cholesterol	1.2 ± 0.3	1.2 ± 0.3	0.794
HDL cholesterol	0.5 ± 0.1	0.5 ± 0.1	0.151
Triglycerides	1.6 ± 1.3	1.7 ± 1.0	0.329
Lipid disorders, %	52 (52.0)	73 (67.0)	0.027
BP, mmHg
Systolic BP	156 ± 12	156 ± 11	0.820
Diastolic BP	91 ± 8	92 ± 8	0.283
Pulse pressure	65 ± 12	64 ± 11	0.247
Heart rate, bpm	74 ± 9	73 ± 9	0.358

Note: Results are given as mean ± SD.

a Calculated by the Cockcroft formula.

Abbreviations: BMI, body mass index; BP, blood pressure.

Table 2 Changes in carotid parameter values measured by ultrasonography (per protocol population)

	Baseline			Last visit			Changea
	n	Mean ± SD (median)	pb	n	Mean ± SD (median)	pb	n	Mean ± SD (median)	pb
CIMT, mm
CC	89	0.758 ± 0.159 (0.737)	0.175	46	0.737 ± 0.195 (0.697)	0.615	46	−0.016 ± 0.149 (−0.027)	0.549
AML	93	0.726 ± 0.161 (0.711)		39	0.703 ± 0.159 (0.676)		39	−0.039 ± 0.197 (−0.033)
Lumen diameter, mm
CC	89	6.518 ± 0.768 (6.519)	0.967	46	6.516 ± 0.652 (6.512)	0.912	46	0.010 ± 0.569 (−0.029)	0.034
AML	93	6.522 ± 0.726 (6.485)		39	6.549 ± 0.627 (6.476)		39	0.299 ± 0.664 (0.336)
Cross-sectional area, mm^2
CC	89	17.55 ± 4.95 (16.52)	0.333	46	17.08 ± 5.95 (16.03)	0.708	46	−0.327 ± 3.719 (−0.635)	0.829
AML	93	16.67 ± 4.67 (16.08)		39	16.29 ± 4.83 (15.32)		39	−0.330 ± 5.362 (−0.287)

a Change observed at last visit compared to baseline.

b Student’s t-test was used to compare the difference between treatment groups.

Abbreviations: AML, amlodipine; CC, candesartan cilexetil; CIMT, carotid intima-media thickness.

Figure 2 Evolution of clinic SBP A) and DBP B) values from baseline (M0) to M24 in hypertensive diabetic patients treated by candesartan cilexetil (CC) or amlodipine (AML).

Patients evaluated in CC group: 89(M0), 86(M1), 81(M2), 79(M3), 71(M6), 71(M9), 64(M12), 62(M15), 59(M18), 46(M21), 36(M24).

Patients evaluated in AML group: 93(M0), 89(M1), 86(M2), 82(M3), 64(M6), 62(M9), 60(M12), 52(M15), 48(M18), 37(M21), 33(M24).

Figure 3 Cross-sectional area (CSA) values at baseline (M0), M12, M24, and at last visit in hypertensive diabetic patients treated by candesartan cilexetil (CC) or amlodipine (AML). No significant change within each treatment group.